López, Saioa
,
Lim, Emilia L.
Horswell, Stuart
Haase, Kerstin http://orcid.org/0000-0002-0944-5618
Huebner, Ariana
Dietzen, Michelle
Mourikis, Thanos P.
Watkins, Thomas B. K.
Rowan, Andrew
Dewhurst, Sally M.
Birkbak, Nicolai J. http://orcid.org/0000-0003-1613-9587
Wilson, Gareth A.
Van Loo, Peter http://orcid.org/0000-0003-0292-1949
Jamal-Hanjani, Mariam
Swanton, Charles http://orcid.org/0000-0002-4299-3018
McGranahan, Nicholas http://orcid.org/0000-0001-9537-4045
Funding for this research was provided by:
Wellcome Trust (211179/Z/18/Z, FC001169, FC001202)
CRUK Lung Cancer Centre of Excellence, Rosetrees Trust, and the NIHR BRC at University College London Hospitals
Cancer Research UK (FC001169, FC001202)
Novo Nordisk Fonden (ID16584)
EIF | Stand Up To Cancer (SU2C-AACR-DT23-17)
Article History
Received: 21 December 2018
Accepted: 28 January 2020
First Online: 5 March 2020
Competing interests
: C.S. receives grant support from Pfizer, AstraZeneca, BMS, Roche-Ventana and Boehringer-Ingelheim. C.S. has consulted for Pfizer, Novartis, GlaxoSmithKline, MSD, BMS, Celgene, AstraZeneca, Illumina, Genentech, Roche-Ventana, GRAIL, Medicxi and the Sarah Cannon Research Institute. C.S. is a shareholder of Apogen Biotechnologies, Epic Bioscience and GRAIL, and has stock options in and is co-founder of Achilles Therapeutics. N.M. has received consultancy fees from Achilles Therapeutics.